Bipolar II Disorder
Cross-source consensus on Bipolar II Disorder from 1 sources and 6 claims.
1 sources · 6 claims
Comparisons
Evidence quality
Other
Other
Other
Highlighted claims
- Bipolar II disorder is characterised by recurrent depressive and hypomanic episodes. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Eligible trial participants are adults aged 18 to 70 years with newly diagnosed bipolar II disorder. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Bipolar II disorder accounts for about 60% of bipolar disorder cases. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Treatment evidence specific to bipolar II disorder remains limited. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Patients may enter the trial while depressed, hypomanic, or in full or partial remission. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Bipolar II disorder has a high disease burden despite historically being considered less severe than bipolar I disorder. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)